Abstract. Roberts The platinum analog CI-973 was selected for clinical study because it is associated with fewer and milder toxicities than either cisplatin or carboplatin in experimental animals, and because it has activity against cisplatin-resistant cell lines in vitro. In this Phase 2 study, 31 women with platinum-resistant or recurrent ovarian carcinoma were treated with CI-973. Three patients achieved a complete response, defined as the disappearance of all measurable disease. The median Kaplan-Meier survival time was estimated to be approximately 7 months from the start of treatment. The most frequently occurring drug-related toxicities were neutropenia, nausea, vomiting, asthenia, anemia, abdominal pain, and diarrhea. Most toxicities were mild or moderate and none resulted in withdrawal from treatment. Despite this favorable toxicity profile, the low response rate of 10% does not support further clinical development of CI-973 as treatment for ovarian cancer.
in vitro and in vivo (4) (5) (6) . Phase I studies in patients with solid tumors indicate that, unlike cisplatin, CI-973 does not appear to cause serious renal toxicity, neurotoxicity, or ototoxicity (7) (8) (9) . CI-973 is myelosuppressive, causing dose-limiting neutropenia, but is not associated with the dose-limiting thrombocytopenia characteristic of carboplatin therapy. This multicenter Phase 2 study was performed to determine the clinical efficacy of CI-973 in patients with advanced ovarian carcinoma that has progressed or recurred after treatment with cisplatin or carboplatin, and to further define the safety profile of this experimental drug.
Patients and methods

Patients
Thirty-one patients with histologically confirmed FIGO stage III or IV measurable epithelial ovarian carcinoma were enrolled in this study. This was a moderately to heavily pretreated patient population, which had had one (15 patients) or two (14 patients) prior chemotherapy regimens for advanced disease. All had received prior cisplatin and/or carboplatin therapy, and 84% were considered platinum-resistant because they had either failed to respond or had relapsed or progressed within 6 months of completing prior platinum-based therapy (Table 1) . Disease progression or recurrence was documented by laparotomy, paracentesis, CT scan, or physical examination 
*Recurred more than 6 months after completing prior platinum therapy.
within one month prior to treatment with CI-973. Patients had not received chemotherapy or radiation therapy for at least 4 weeks prior to treatment. Patients who had received prior intraperitoneal chemotherapy or abdominal or pelvic radiation were not eligible for treatment with CI-973. At baseline, patients had a creatinine clearance >1 mL sec-1, an ALT level < twice the upper limit of normal of the institution, and a total bilirubin level < 34.2 ~tmol L -l. Baseline hematologic criteria included an absolute granulocyte count of > 1.5 x 10 9 L 1 and platelet count of > 100 x 10 9 L -1. Measurements of hematologic parameters and blood chemistries were performed weekly during treatment. Urinalysis, measurement of serum CA125 levels, and creatinine clearance estimates were performed every 3 weeks. Monitoring for CI-973-related toxicity occurred throughout the study and an evaluation of toxicity occurred at the end of each treatment period. Toxicities were graded according to the National Cancer Institute common toxicity criteria.
Drug administration
CI-973 was administered as a 30-minute intravenous infusion once every 21 days. The starting dose was 190 mg m -2, which could be increased or decreased by 25% for subsequent doses, depending on each patient's tolerance of therapy. Patients who had progression were withdrawn from the study. Patients whose best response to therapy was stable disease could receive up to four courses of CI-973. Patients who achieved a complete or partial response to treatment received CI-973 until relapse or recurrence.
Response criteria
Sentinel lesions were measured either by physical exam or CT scan at baseline and 3 weeks after each dose. Objective response was determined by comparing the size of measurable sentinel lesions after at least one course of treatment to the size at baseline according to standard criteria for the evaluation of solid tumors (1°'11). A complete response (CR) was defined as the disappearance of all known disease. A partial response (PR) was a 50% or greater decrease in the sum of the product of cross-sectional diameters (tumor size) of sentinel lesions and no appearance of new lesions. Both complete and partial responses had to be confirmed at least 3 weeks after the initial assessment of response. Stable disease was defined as a less than 50% decrease and less than 25% increase in tumor size, with no appearance of new lesions. Progressive disease was defined as a 50% or greater increase in the size of any one sentinel lesion, or the appearance of a new lesion. Changes in CA125 levels were not included in definitions of response.
Results
Three of 31 patients (9.7%) responded to treatment ( 
months).
No treatment-related deaths occurred. At last contact, 13 patients had died of their ovarian cancer. The median Kaplan-Meier survival time was estimated to be 224 days, or 7.4 months (Fig. 1) . No patient was withdrawn from the study because of treatment-related toxicity. Neutropenia was doselimiting. The median nadir absolute neutrophil count was 1.200 x 109 L -1 and the nadir occurred a median of 15 days after dosing. Filgrastim was used at the investigators' discretion. Fifteen patients (48%) experienced grade W neutropenia (<0.500 x 109 L-J). The median time to recovery (~>1.000x109 L -1) was 7 days, with a range of 2-15 days. Two patients experienced treatment-associated febrile neutropenia, and one of these patients subsequently developed sepsis. Both patients recovered within 5 days. Three other grade IV adverse events occurred in one patient each (vomiting, headache, and anemia). These events were not considered treatment-related.
The most frequently occurring CI-973-associated toxicities were neutropenia, nausea and/or vomiting, asthenia, anemia, abdominal pain, and diarrhea (Table  3) . Most of the occurrences were mild or moderate. Neurotoxicity was infrequent and consisted largely of mild, reversible paresthesias. One patient experienced intermittent tinnitus, which was considered possibly treatment-related even though it was present at baseline. There were no cases of nephrotoxicity.
Discussion
CI-973 was developed with the goal of obtaining an anticancer agent that was active against cisplatin- resistant tumors and was not associated with the doselimiting toxicities characteristic of cisplatin. Preclinical studies were promising: not only was the antitumor activity of CI-973 comparable to cisplatin and superior to carboplatin against cisplatin-sensitive tumor cell lines, CI-973 also exhibited a high degree of activity against several cell lines that were highly cisplatinresistant ~4-6~. Animal toxicology studies showed that dose-limiting toxicity primarily targeted the hematopoietic system and gastrointestinal tract. Unlike cisplatin, CI-973 was not ototoxic and did not produce renal toxicity. There was also no evidence of neurotoxicity. Phase I studies in patients with solid tumors established that neutropenia was the doselimiting toxicity, and confirmed that CI-973 was not seriously nephrotoxic, neurotoxic, or ototoxic (7-9). Furthermore, it did not cause severe thrombocytopenia, even in patients who developed Grade IV neutropenia.
The results obtained in this Phase 2 study have confirmed all of these previously reported data. The Phase 2 program was designed to determine the level of antitumor activity of CI-973 against a variety of solid tumors. Ovarian cancer was chosen as one of the tumor types for study because of its relative sensitivity to initial treatment with platinum compounds and the problem of the development of platinum resistance ~3~. Given that CI-973 had in vitro activity against cisplatin-resistant cell lines, it was a promising candidate for the treatment of advanced ovarian cancer. However, the activity of CI-973 against advanced epithelial ovarian cancer in this study was minimal: the observed response rate was only 10% (3/ 31 patients) and in one patient the response was only of 2 months duration. Furthermore, two of the responses occurred among the group of five patients whose cancer was potentially platinum-sensitive. A response rate ~> 20% would have justified further study of CI-973 in ovarian cancer. Although the observed response rate of 10% was not statistically different from a response rate of 20% (Z value = 1.17), the sample size of 31 patients provided only 47% power to detect a difference of 10%. Therefore, these results do not support the development of CI-973 as single-agent therapy for this indication. In addition, they suggest that preclinical models of platinum resistance may not always correlate with clinical activity in patients with ovarian cancer. It may be necessary to better define such models to enhance the prospect of identifying a platinum analog with clinical activity in patients with refractory ovarian cancer. However, with its relatively mild toxicity profile, CI-973 may be a suitable candidate for inclusion in a dose intensification chemotherapy regimen. For example, the dose-limiting neutropenia was of brief duration and was rarely associated with infection. Therefore, concurrent therapy with GCSF or GMCSF could be expected to overcome this toxicity and allow the use of higher, possibly more effective doses.
